Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 05, 2018 08:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Announces Management Changes

BERKELEY, Calif., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) a biopharmaceutical company with three distinct immunotherapy technologies, today announced that Jennifer Lew...
January 04, 2018 16:01 ET | Source: Aduro Biotech, Inc.

Aduro Biotech to Present at the 36th Annual J.P. Morgan Healthcare Conference

BERKELEY, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, will present...
December 20, 2017 08:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Expands Leading Intellectual Property Position in STING Field with Newly Issued Patent

BERKELEY, Calif., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced that the United...
December 18, 2017 08:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Announces the Initiation of a Phase 1/2 Clinical Trial of BION-1301, a Novel Anti-APRIL Antibody, for the Treatment of Multiple Myeloma

BERKELEY, Calif., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced that the first...
December 12, 2017 08:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Provides Update on CRS-207 Programs

BERKELEY, Calif., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today provided an update on its...
December 11, 2017 16:01 ET | Source: Aduro Biotech, Inc.

Aduro Biotech to Host a Program Update Call

BERKELEY, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced that the company...
November 21, 2017 01:00 ET | Source: Aduro Biotech, Inc.

Wiebe Olijve, wetenschappelijk adviseur van Aduro Biotech en medeoprichter van Aduro Biotech Europe, geëerd met koninklijke onderscheiding

BERKELEY, Californië, Verenigde Staten en OSS, Nederland, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), een biofarmaceutisch bedrijf met drie afzonderlijke...
November 21, 2017 01:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Scientific Advisor and Co-Founder of Aduro Biotech Europe Wiebe Olijve Honored with Royal Decoration

BERKELEY, Calif. and OSS, Netherlands, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq: ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today...
November 10, 2017 08:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Announces Promising Preclinical Data that Validate Anti-CTLA-4 Antibody ADU-1604

BERKELEY, Calif., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced data from...
November 01, 2017 09:05 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Announces Upcoming Data Presentations at the 59th American Society of Hematology Annual Meeting

BERKELEY, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced preclinical data...